This study is in progress, not accepting new patients
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
a study on Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Lee-May Chen
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Lee-May Chen
Dr. Lee-may Chen is the Division Director and Program Director for the UCSF/KPSF Gynecologic Oncology Fellowship Program. She is deeply committed to education and improving the outcomes of gynecologic cancer care. Since 2008, I have been the director of the UCSF Gynecologic Cancer Risk Program.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT03038100
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated